All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance
During the 7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to Mikkael Sekeres, Sylvester Comprehensive Cancer Center, Miami, US. We asked, What are novel strategies to treat higher-risk MDS?
What are novel strategies to treat higher-risk MDS?
Sekeres firstly suggests a new method to define MDS risk by combining the IPSS with genetic mutational status. He then evaluates novel strategies for higher-risk MDS, including combination therapies and molecular profiling.
P-2001 study: Which patients benefit most from pevonedistat plus azacitidine?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Mikkael Sekeres, Sylvester Comprehensive Cancer Center, Miami, US,...
Practice-changing abstracts in myelodysplastic syndromes
World-leading experts in MDS shared the top abstracts from ASH 2020 that they believed could have the greatest impact on clinical practice.
Subscribe to get the best content related to MDS delivered to your inbox